Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs.
Zhengye Biotechnology Holding stock last closed at $10.69, up 14.7% from the previous day, and has decreased N/A in one year. It has underperformed other stocks in the Biotechnology industry by N/A percentage points. Zhengye Biotechnology Holding stock is currently +205.43% from its 52-week low of $3.50, and -25.24% from its 52-week high of $14.30.
There are currently 47.17M shares of ZYBT outstanding. The market capitalization of ZYBT is $504.21M. In the last 24 hours, 229,000 ZYBT shares were traded.
You need an online brokerage account to access the NASDAQ market and buy ZYBT stock.
Based on our analysis, eToro is the best place to buy stocks. Here's why:
Get $10 towards your stock purchase by opening an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've picked the best brokerage, it's time to fill out some personal information so you can buy ZYBT today.
Now that you have finished signing up on investing apps, you need to deposit funds:
Check out the video below if you need help depositing money into your investment account.
After you have selected the best place to buy Zhengye Biotechnology Holding stock, it's important to analyze their stock prior to investing, so you truly comprehend the risk as well as the upside.
WallStreetZen was created to help average investors do better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on ZYBT's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge ZYBT's fair value.
Using relative valuations ratios:
You can access more valuation analysis on ZYBT's stock here.
Last year, ZYBT earnings were $1.58M. Over the last 2 year, ZYBT's earnings have grown by -51.74% per year. This was slower than the Biotechnology industry average of 8.79%.
Last year, ZYBT revenue was $25.99M. In the last 2 year, ZYBT's revenue has gone up by -17.32% per year. This was slower than the Biotechnology industry average of 67.8%.
Dig into ZYBT's earnings and revenue performance here.
In the past year, insiders at ZYBT have not bought or sold any shares.
Get more info about who owns ZYBT shares here.
No, Zhengye Biotechnology Holding doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
There are two main options:
Press the Open Trade button and eToro will place your order.
If you require more assistance buying stocks on eToro, click the helpful video below:
Now that you own some ZYBT stock, you'll want to stay up-to-date on your new company.
Create a watchlist to keep track of your ZYBT stock.
To reiterate, here are the 6 steps you need to take to buy Zhengye Biotechnology Holding stock right now:
If you need a online brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to monitor your new investment in Zhengye Biotechnology Holding, click below.